Search
Search Constraints
You searched for: Author/Creator Loaiza-Perez, AndreaLimit your search
- Loaiza-Perez, Andrea [remove] 1
- 616.994 1
- Breast cancer -- Stem cells -- Endocrine resistance -- Endocrine therapy -- Disparities 1
- Cancer -- Periodicals 1
- Cancer -- Périodiques 1
- Electronic journals 1
- Neoplasms -- Periodicals 1
- breast cancer stem cell (BCSC) -- cancer stem cell (CSC) -- estrogen receptor (ER) -- estrogen receptor alpha (ERα) -- progesterone receptor (PR) -- human epidermal growth factor receptor 2 (Her2) -- endocrine therapy (ET) -- epidermal growth factor receptor (EGFR) -- cyclin dependent kinase (CDK) -- mammalian target of rapamycin (mTOR) -- aryl hydrocarbon receptor (AhR) -- Aminoflavone (AF) -- phosphatidyl inositol-3-kinase (PI3K) -- Hypoxia inducible factor (HIF) -- hypoxia inducible factor 1 alpha (HIF1α) -- hypoxia inducible factor 2 alpha (HIF2α) -- insulin growth factor (IGF) -- aldehyde dehydrogenase (ALDH) -- death associated factor 6 (DAXX) -- 2, 3, 7, 8‐tetrachlorodibenzo‐p‐dioxin (TCDD) -- cyclin dependent kinase 4 (CDK4) -- progression-free survival (PFS) -- cyclooxygenase 2 (COX-2) -- epithelial to mesenchymal transition (EMT) -- triple-negative breast cancer (TNBC) -- interleukin-6 (IL-6) -- patient derived xenograft (PDX) -- relapse-free survival (RFS) -- relapse risk score (RRS) -- disease-free survival (DFS) -- disease-specific survival (DSS) -- vascular endothelial growth factor receptor 2 (VEGFR2) -- zinc finger MYND-type containing 8 (ZMYND8) -- γ-secretase inhibitors (GSIs) -- delta-like-ligand (DLL) -- Jagged-1 (JAG1) -- Jagged-2 (JAG2) -- Trial Assigning Individualized Options for Treatment Rx (TAILORx) -- aromatase inhibitors (AIs) -- hypoxia response element (HRE) -- disintegrin metalloprotease (ADAM) -- phosphotyrosine binding protein (NUMB) -- CREB binding protein (CBP) -- notch inhibitor domain (NID) -- activation complex (AC) -- focal adhesion kinase (FAK) 1